



THE GENERAL COURT OF MASSACHUSETTS
STATE HOUSE, BOSTON, 02133-1053

FOR IMMEDIATE RELEASE

CONTACT

Stephen Acosta, Office of Senator Cindy F. Friedman
Stephen.Acosta@masenate.gov

Jared Magee, Office of Representative John J. Lawn, Jr.
Jared.Magee@mahouse.gov

(BOSTON–12/27/2024) The Conference Committee on pharmaceutical access, cost, and transparency, as well as on health care market oversight legislation today filed reports resolving the differences between the bills passed by the Senate and House of Representatives. **Senate Chair Cindy F. Friedman (D-Arlington)** and **House Chair John J. Lawn, Jr. (D-Watertown)** issued the following statement on the conference committee reports:

“As the Commonwealth continues to respond to the collapse of Steward Health Care, and consumers face increasing health care costs, we are proud to be able to deliver important reforms to the operation and oversight of health care markets in Massachusetts. Together, these two conference committee reports ensure that patients will pay less for medication by limiting out-of-pocket costs for essential prescription drugs, promote affordability of health insurance premiums for consumers, regulate pharmacy benefit managers, and strengthen state oversight by increasing market transparency and bringing key health care industry players to the table to better understand what is driving costs. We thank the members of the conference committee for their work on these very complex pieces of legislation over the past few months, and look forward to presenting the conference reports to the full Senate and House for acceptance before the end of the legislative session next week.”

###

The pharmaceutical legislation, *An Act relative to pharmaceutical access, costs and transparency* (S.2520/H.4910), has been filed in the Senate, the health care market oversight legislation, *An Act enhancing the market review process* (H.4653/S.2881), has been filed in the House of Representatives.